AstraZeneca Secures Etcamah Breast Cancer Approval in Combination With CDK4/6 Inhibitors for US Patients
AstraZeneca’s Etcamah (camizestrant) has won US FDA approval alongside CDK4/6 inhibitors for HR-positive, HER2-negative breast cancer patients who develop an ESR1 mutation before disease progression.
